New kidney disease treatment enters human testing

NCT ID NCT06721143

Recruiting now Disease control Sponsor: AION Healthspan, Inc. Source: ClinicalTrials.gov ↗

First seen Apr 17, 2026 · Last updated Apr 22, 2026 · Updated 1 time

Summary

This study is testing whether two intravenous infusions of an experimental drug called AION-301 are safe and might help people with moderate chronic kidney disease. Researchers will compare the drug to a placebo in 36 participants to see if it reduces kidney-related symptoms or slows disease progression. Participants will receive two infusions and take vitamins for 90 days, with follow-up visits over 6 to 24 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE STAGE 3 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

SouthCoast Research Center, Inc.
RECRUITING

Miami, Florida, 33136, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Miami, Leonard M. Miller School of Medicine
RECRUITING

Miami, Florida, 33136, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CHRONIC KIDNEY DISEASE STAGE 3